Abstract

Aim

In this study, 5-fluorouracil (5-FU) is delivered to target colon without the interference of mononuclear phagocyte system (MPS).

Methods

Outer membrane vesicles (OMVs) were used as the biological shield to disguise mesoporous silica (MSN) and 5-FU. OMVs-MSN-5-FU were prepared by high pressure co-extrusion, and characterised on the basis of size, drug loading, transmission electron microscope, infra-red spectroscopy, differential scanning calorimetry, thermal gravity analysis, % in vitro release, MTT assay, cell uptake and in vivo imaging.

Results

OMVs-MSN-5-FU with −18.22 ± 0.17 mV zeta potential and 90.4 ± 9.1 nm size were used for oral treatment of colon cancer. Drug loading of the drug was 50.22%±0.17 (w/w). The cumulative release of OMVs-MSN-5-FU reached 75.07%±0.94 in tumour microenvironment. The percentage of cell viability of OMVs-MSN-5-FU was 33.75%±2.73. In vivo experiments results confirmed that OMVs-MSN-5-FU could be taken up by colon cancer cells.

Conclusions

The study provided a promising nano platform for the targeting treatment of colon cancer.

中文翻译：

---

生物膜包裹的纳米药物递送系统用于治疗结肠癌。

摘要

目标

在这项研究中，将5-氟尿嘧啶（5-FU）递送至靶结肠，而不会干扰单核吞噬细胞系统（MPS）。

方法

外膜囊泡（OMVs）被用作掩盖中孔二氧化硅（MSN）和5-FU的生物屏蔽。通过高压共挤出制备OMVs-MSN-5-FU，并根据尺寸，载药量，透射电子显微镜，红外光谱，差示扫描量热法，热重分析，体外释放％，MTT进行表征分析，细胞摄取和体内成像。

结果

具有-18.22±0.17 mV zeta电位和90.4±9.1 nm大小的OMVs-MSN-5-FU用于口服治疗结肠癌。该药物的载药量为50.22％±0.17（w / w）。在肿瘤微环境中，OMVs-MSN-5-FU的累积释放达到75.07％±0.94。OMVs-MSN-5-FU的细胞活力百分比为33.75％±2.73。体内实验结果证实，OMVs-MSN-5-FU可被结肠癌细胞吸收。

结论

该研究为结肠癌的靶向治疗提供了有希望的纳米平台。